J Korean Breast Cancer Soc.  2002 Dec;5(4):311-318. 10.4048/jkbcs.2002.5.4.311.

Neoadjuvant Chemotherapy for the Local Advanced Breast Cancer

Affiliations
  • 1Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. bwpark@yumc.yonsei.ac.kr
  • 2Department of Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea.
  • 3Department of Surgery, College of Medicine, Hallym University, Pyungchon, Korea.
  • 4Department of Surgery, College of Medicine, Pochon Cha University, Pocheon, Korea.

Abstract

PURPOSE: The definition of locally advanced breast cancer (LABC) includes stage III breast cancer. In order to investigate the factors influencing on the final outcome we analysed the data of LABC patients that received neoadjuvant chemotherapy prior to definitive surgery.
METHODS
122 LABC patients, who underwent neoadjuvant chemotherapy between 1980 and 1997, were included for the analysis. Clinical responses to neoadjuvant chemother apy were classified as complete response (CR), partial response (PR), and no response (NR). Overall survival (OS), Loco-regional relapse free survival (LRRFS), and distant relapse free survival (DRRFS) probabilities were investigated according to initial clinical stage, clinical response to neoadjuvant chemotherapy, and pathologic stage after neo adjuvant chemotherapy. Statistical analyses were performed with chi2-test, Kaplan-Meier, and Cox-regression methods using SPSS.
RESULTS
The mean age at diagnosis was 47 years old (range 31~73) and median follow-up period was 61.6 months (range 3~227 months). Among 122 LABC patients, 69 (56.6%) were included in stage IIIA, 37 (30.3%) in stage IIIB, and 16 (13.1%) in IIIC at diagnosis. 10 patients (8.2%) have shown CR, 85 (69.7%) patients PR, and the remaining 27 (22.1%) patients showed NR. The overall response rate to neoadjuvant chemotherapy was 77.5%. However, only 51 (41.8%) were demonstrated to have pathologically down-staged results. There were 32 loco-regional recurrences and 59 distant metastases. All of the initial clinical stage, clinical response to neoadjuvant chemotherapy, and pathologic stage influenced the final outcome of 10 year OS, LRRFS, DRFS. However, in multivariate analysis pathologic stage after neoadjuvant chemotherapy was the most influencing factor on the final outcome.
CONCLUSION
Pathologic stage after neoadjuvant chemotherapy could be the most important prognostic factor of the LABC.

Keyword

Locally advanced breast cancer; Neoadjuvant induction chemotherapy; Clinical response; Prognostic factor

MeSH Terms

Breast Neoplasms*
Breast*
Chemotherapy, Adjuvant
Diagnosis
Drug Therapy*
Follow-Up Studies
Humans
Middle Aged
Multivariate Analysis
Neoplasm Metastasis
Recurrence

Cited by  1 articles

Neoadjuvant Chemotherapy with Docetaxel and Adriamycin in Breast Cancer; Clincopathologic Factors Influencing to Response Rate
Dong Won Ryu, Chang Wan Jun, Chung Han Lee
J Breast Cancer. 2008;11(2):89-94.    doi: 10.4048/jbc.2008.11.2.89.

Full Text Links
  • JKBCS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr